US regulator calls for divestment for Endo Health’s acquisition of Boca Pharmacal to proceed

2 February 2014

US specialty health care firm Endo Health Solutions (Nasdaq: ENDP) and its takeover target generic drugmaker Boca Pharmacal have agreed to a settlement resolving US Federal Trade Commission charges that Endo’s $225 million cash acquisition of Boca would be anticompetitive (The Pharma Letter August 29, 2013).

Under the settlement, the companies will relinquish their rights to market and distribute four generic multivitamin fluoride drops for children, and will sell three other generic drugs in development.

The proposed settlement will preserve competition in the pharmaceutical markets for four prescription generic multivitamin drop products given to children in the USA who do not have access to fluoridated water. In addition, the FTC’s settlement will preserve future competition for three generic drugs:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK